Helicobacter Pylori Infection | Medibuddy
17th July 2023

Helicobacter Pylori Infection

H.pylori is a gram-negative bacterium that has been implicated in a number of gastrointestinal pathologies.

Pathology Details
Chronic gastritis H. pylori can predispose patients to other conditions, such as neoplasm
Peptic ulcer disease H. pylori has been implicated in:

  • 90% of Duodenal Ulcers (DU)
  • 70-80% of Gastric Ulcers (GU)
Gastric adenocarcinoma H. pylori associated with a 1-2% lifetime risk of gastric adenocarcinoma
B cell lymphoma of MALT tissue 75% of MALT lymphomas are successfully treated with H. pylori eradication therapy

Table 9: Sequelae of chronic Helicobacter pylori infection.

Investigations (BSG guidelines)

  • 1st line: Urea breath test/stool antigen testing
    • Requires a 2-week PPI washout period and 4 weeks for antibiotics
    • Urea breath test is the preferred investigation to test for eradication post treatment
  • 2nd line: Serology (does not differentiate between active and past infection, so cannot be used for retesting)

If a patient is undergoing OGD, the endoscopist can take biopsies to perform a rapid urease test (also known as the CLO test – Campylobacter-Like Organism) to test for H. pylori.

Treatment

7 days high-dose PPI + amoxicillin + metronidazole/clarithromycin

  • If the patient is penicillin allergic, use high-dose PPI + metronidazole + clarithromycin (7 days).

Antiulcer medication

Reduction/neutralisation of stomach acid:

  • Proton pump inhibitors (antisecretory)
  • Histamine-2 receptor antagonists (antisecretory)
  • Antacids (neutralising)

Other mechanisms:

  • Sucralfate (forms a protective barrier over the ulcer)
Mobile app screenshots

Take your subscriptions with you

Our mobile app allows you to access your interview and exam question banks wherever you are.